electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.0277 USD -1.43%
Market Cap: 105m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Net Issuance of Common Stock
$8.3m
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Net Issuance of Common Stock
-$500m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
Boston Scientific Corp
NYSE:BSX
Net Issuance of Common Stock
$219m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Net Issuance of Common Stock
-$966m
CAGR 3-Years
9%
CAGR 5-Years
-161%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Net Issuance of Common Stock
$345.3m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
104.3m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.4922 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Net Issuance of Common Stock?
Net Issuance of Common Stock
8.3m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Net Issuance of Common Stock amounts to 8.3m USD.

What is electroCore, Inc.'s Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
-32%

Over the last year, the Net Issuance of Common Stock growth was 2%. The average annual Net Issuance of Common Stock growth rates for electroCore, Inc. have been -32% over the past three years .

Back to Top